Levosimendan in Acute Kidney Injury Study

Inclusion Criteria: * Clinically diagnosed adult patients with AKI Exclusion Criteria: * Failure to obtain written consent to participate from patient or legal representative (by deferred consent) * Patients entering the ICU for post-operative observation with an estimated length of stay less than 24 hrs. * Moribund patients * Patients under the age of 18 * Pregnancy * Patients suffering from pre-existing renal failure (elevated NGAL values without apparent rise in creatinine values) * Renal replacement therapy initiated before admission due to Chronic Kidney Disease * Hypersensitivity to levosimendan experienced by previous treatments * Severe hypotension and tachycardia * Significant mechanical obstruction affecting ventricular filling or outflow or both. * Severe hepatic impairment (ALAT/ASAT\>400U/L) * Patients will be excluded if the treating physician judges that study participation is undesirable for medical, medical-ethical or other reasons * Known history of Torsades de Pointes